UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.

The Phase 3 trial sought to evaluate dapirolizumab pegol plus standard of care in people living with moderate-to-severe lupus and met its primary goal of improvement after 48 weeks compared with ...

and lupus therapies litifilimab and dapirolizumab pegol. Last month, the FDA ended a five-year drought in new therapies for ALS when it approved Amylyx' Relyvrio (sodium phenylbutyrate and ...

Steroid Use in SLE Half of lupus patients taking dapirolizumab pegol achieved response at week 48 compared with one third of patients taking placebo. News, November 25, 2024 ACR 2024 AI Robot ...

Steroid Use in SLE Half of lupus patients taking dapirolizumab pegol achieved response at week 48 compared with one third of patients taking placebo. Medscape Medical News, November 25 ...